Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects.

Hausner H, Derving Karsbøl J, Holst AG, Jacobsen JB, Wagner FD, Golor G, Anderson TW

Clinical pharmacokinetics1 Nov 2017Cited by 51 (Europe PMC)

PMID28349387PMCIDPMC5648738DOI10.1007/s40262-017-0532-6PepBankPUB-28349387

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialPharmacokinetics
In healthy subjects, semaglutide at steady state did not change metformin exposure (AUC ratio) outside the pre-specified interval.
In plain wordsIn healthy people, semaglutide did not meaningfully change how much metformin entered the blood.
Peptide
Semaglutide
Outcome
No significant changeMetformin AUC with semaglutide
Study
n: not reported in source
Comparator
Same drug before semaglutide
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Estimated area under the plasma concentration-time curve ratios for all concomitant medications before and with semaglutide treatment were within the pre-specified interval.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects received metformin (500 mg twice daily for 3.5 days), warfarin (25 mg, single dose), atorvastatin (40 mg, single dose) or digoxin (0.5 mg, single dose) before and with subcutaneous semaglutide treatment at steady state (1.0 mg).
Report a problemFND-2834938701
02HumanNon-randomized trialPharmacokinetics
In healthy subjects, semaglutide at steady state did not change warfarin exposure (AUC ratio) outside the pre-specified interval.
In plain wordsIn healthy people, semaglutide did not meaningfully change how much warfarin entered the blood.
Peptide
Semaglutide
Outcome
No significant changeWarfarin AUC with semaglutide
Study
n: not reported in source
Comparator
Same drug before semaglutide
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Estimated area under the plasma concentration-time curve ratios for all concomitant medications before and with semaglutide treatment were within the pre-specified interval.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects received metformin (500 mg twice daily for 3.5 days), warfarin (25 mg, single dose), atorvastatin (40 mg, single dose) or digoxin (0.5 mg, single dose) before and with subcutaneous semaglutide treatment at steady state (1.0 mg).
Report a problemFND-2834938702
03HumanNon-randomized trialPharmacokinetics
In healthy subjects, semaglutide at steady state did not change atorvastatin exposure (AUC ratio) outside the pre-specified interval.
In plain wordsIn healthy people, semaglutide did not meaningfully change how much atorvastatin entered the blood.
Peptide
Semaglutide
Outcome
No significant changeAtorvastatin AUC with semaglutide
Study
n: not reported in source
Comparator
Same drug before semaglutide
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Estimated area under the plasma concentration-time curve ratios for all concomitant medications before and with semaglutide treatment were within the pre-specified interval.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects received metformin (500 mg twice daily for 3.5 days), warfarin (25 mg, single dose), atorvastatin (40 mg, single dose) or digoxin (0.5 mg, single dose) before and with subcutaneous semaglutide treatment at steady state (1.0 mg).
Report a problemFND-2834938703
04HumanNon-randomized trialPharmacokinetics
In healthy subjects, semaglutide at steady state did not change digoxin exposure (AUC ratio) outside the pre-specified interval.
In plain wordsIn healthy people, semaglutide did not meaningfully change how much digoxin entered the blood.
Peptide
Semaglutide
Outcome
No significant changeDigoxin AUC with semaglutide
Study
n: not reported in source
Comparator
Same drug before semaglutide
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Estimated area under the plasma concentration-time curve ratios for all concomitant medications before and with semaglutide treatment were within the pre-specified interval.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects received metformin (500 mg twice daily for 3.5 days), warfarin (25 mg, single dose), atorvastatin (40 mg, single dose) or digoxin (0.5 mg, single dose) before and with subcutaneous semaglutide treatment at steady state (1.0 mg).
Report a problemFND-2834938704
05HumanNon-randomized trialPharmacokinetics
In healthy subjects, semaglutide did not affect the maximum plasma concentration of metformin, warfarin, atorvastatin or digoxin to a relevant degree.
In plain wordsIn healthy people, semaglutide did not meaningfully change the peak blood levels of metformin, warfarin, atorvastatin or digoxin.
Peptide
Semaglutide
Outcome
No significant changeMaximum plasma concentration of concomitant medications
Study
n: not reported in source
Comparator
Same drug before semaglutide
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
In addition, semaglutide did not affect maximum plasma concentration of concomitant medications to a relevant degree.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects received metformin (500 mg twice daily for 3.5 days), warfarin (25 mg, single dose), atorvastatin (40 mg, single dose) or digoxin (0.5 mg, single dose) before and with subcutaneous semaglutide treatment at steady state (1.0 mg).
Report a problemFND-2834938705
06HumanNon-randomized trialPharmacokinetics
In healthy subjects, no clinically relevant change in INR response to warfarin was observed with semaglutide co-administration.
In plain wordsIn healthy people, semaglutide did not meaningfully change the blood-clotting response to warfarin.
Peptide
Semaglutide
Outcome
No significant changeInternational normalised ratio response to warfarin
Study
n: not reported in source
Comparator
Same drug before semaglutide
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Furthermore, no clinically relevant change in international normalised ratio response to warfarin was observed with semaglutide co-administration.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects received metformin (500 mg twice daily for 3.5 days), warfarin (25 mg, single dose), atorvastatin (40 mg, single dose) or digoxin (0.5 mg, single dose) before and with subcutaneous semaglutide treatment at steady state (1.0 mg).
Report a problemFND-2834938706
07HumanNon-randomized trialSafety outcome
In healthy subjects, most adverse events with semaglutide were mild or moderate and mostly gastrointestinal, and comparable to semaglutide alone.
In plain wordsIn healthy people, side effects were mostly mild or moderate and digestive, and similar to semaglutide taken alone.
Peptide
Semaglutide
Outcome
Not applicableAdverse events with semaglutide
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Studied dose
1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Most adverse events with semaglutide treatment were mild or moderate.
2 context sentences(design, population, supporting numbers)
Summary · context
Adverse events with semaglutide and co-administered medication were comparable to those reported during treatment with semaglutide alone, and were mostly gastrointestinal related.
Summary · context
Subjects received metformin (500 mg twice daily for 3.5 days), warfarin (25 mg, single dose), atorvastatin (40 mg, single dose) or digoxin (0.5 mg, single dose) before and with subcutaneous semaglutide treatment at steady state (1.0 mg).
Report a problemFND-2834938707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT02243098

Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects

Novo Nordisk A/Sn = 3116 Sept 2014 to 7 Apr 2015

Diabetes · Healthy

Trial page ClinicalTrials.govUpdated 4 Apr 2017

CompletedPhase 1NCT02022254

Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects

Novo Nordisk A/Sn = 2417 Dec 2013 to 28 Aug 2014

Diabetes · Diabetes Mellitus, Type 2 · Healthy

Trial page ClinicalTrials.govUpdated 4 Apr 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.